Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR have recently announced a significant financing facility agreement worth $600 million. The agreement involves Bausch Receivables Funding LP, a subsidiary of Bausch Health, entering into a non-recourse financing facility with KKR and its credit funds and accounts. This facility will be backed by specific accounts receivables originated by anothe..
Crystal Pharmatech, a leading pharmaceutical technology company, has received the prestigious "Best Partner" award from Allorion Therapeutics for its exceptional services in supporting a First-in-Human (FIH) study. This recognition highlights Crystal Pharmatech's expertise and commitment to conducting polymorph screening, preformulation, and formulation development for new drug entities (NCE). I..
New data released by BrainStorm Cell Therapeutics has revealed promising results for their ALS treatment, NurOwn. The Phase 3 trial showcased a significant reduction in the neurodegeneration biomarker, NfL, among participants who received NurOwn compared to those who were given a placebo. The decision to analyze biomarker data was influenced by recent FDA approvals for ALS drugs and the correlat..
a professor at UCL, stated that these results are significant because they provide evidence that Tecentriq can be a viable treatment option for NSCLC patients who cannot tolerate platinum-based chemotherapy. Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, allowing the body's immune system to recognize and attack the tumor. It has already been..
Broncus Holding Corporation (HKG:2216) has successfully completed the first case of registered clinical trials for its targeted lung denervation radiofrequency ablation system. The trial, led by Professor Luo Fengming at the West China Hospital of Sichuan University, is a multi-center study aimed at evaluating the safety and effectiveness of Broncus' denervation ablation system in treating Chron..
중국의 HUTCHMED는 HMPL-415라는 새로운 약물의 상이 활성점 저해제로 작용하는 알로스테릭 선택적 저해제인 SHP2를 대상으로 한 1상 연구를 개시했다고 발표했다. 이 임상시험은 고도의 악성 고형 종양을 가진 환자를 대상으로 HMPL-415의 안전성, 내성, 약동학 및 예비 효능 프로파일을 평가하는 연구이며, 약 80명의 환자를 예상하고 있다. 이 연구는 중증도 증가 단계의 일부로 환자를 포함하고, 추천된 2상 용량이 결정된 이후 추가 환자를 모집할 예정이다. HMPL-415의 대표적인 주요 조사원은 중산 병원 중대학의 텐슈 류 박사와 훈난 암병원의 논 앙 박사이다. 자세한 내용은 clinicaltrials.gov에서 NCT05886374 식별자를 사용하여 확인할 수 있다.
Biophytis, a clinical-stage biotechnology company, has submitted an application for authorization with the FDA to initiate the SARA-31 Phase 3 study in sarcopenia. The purpose of this study is to assess the effectiveness and safety of Sarconeos (BIO101) in treating sarcopenic patients who are at risk of mobility disability. The company anticipates receiving a response from regulatory authorities..
